Year: 2002
Type: review
Abstract: interleukin granulocyte-macrophage colony-stimulating factor leukemia inhibitory factor oncostatin M ciliary neurotrophic factor novel neurotrophin-1/B cell-stimulating factor-3/cardiotrophin-like cytokine cardiotrophin-1 LIF receptor thymic stromal lymphopoietin X-linked severe combined immunodeficiency natural killer TSLP receptor interferon Cytokines represent a diverse group of molecules that collectively exert a wide range of actions (1Leonard W.J. Paul W.E. Fundamental Immunology. 4th Ed. Lippincott-Raven Publishers, Philadelphia1999: 741-774Google Scholar). The term cytokine is rather general, technically referring to a molecule made by one cell that acts on another, but cytokines are primarily growth factors and hormones of the immune and hematopoietic systems. The term broadly encompasses many of the interleukins and colony-stimulating factors (which are also referred to as type I cytokines) and interferons (which sometimes are referred to as type II cytokines) (1Leonard W.J. Paul W.E. Fundamental Immunology. 4th Ed. Lippincott-Raven Publishers, Philadelphia1999: 741-774Google Scholar). Certain molecules, such as erythropoietin, thrombopoietin, growth hormone, and prolactin, although not classically thought of as typical cytokines, have similar structures and signaling mechanisms to type I cytokines (1Leonard W.J. Paul W.E. Fundamental Immunology. 4th Ed. Lippincott-Raven Publishers, Philadelphia1999: 741-774Google Scholar). Many individual cytokines are themselves pleiotropic, exerting multiple actions, and particularly in vitro, many cytokines have overlapping actions (2Paul W.E. Cell. 1989; 57: 521-524Abstract Full Text PDF PubMed Scopus (200) Google Scholar, 3Leonard W.J. Curr Opin. Immunol. 1994; 6: 631-635Crossref PubMed Scopus (53) Google Scholar). There are multiple different possible mechanisms that can explain pleiotropic and overlapping actions for different cytokines. Pleiotropic actions can be explained by the presence of receptors for a cytokine on multiple lineages or by a cytokine having the ability to activate multiple signaling pathways wherein different signaling pathways differentially contribute to different functions. Overlapping actions by different cytokines can be explained by similar cellular distributions of specific receptors for different cytokines as well as by the sharing of signaling pathways, which particularly occurs when different receptors share similar motifs that mediate the coupling to the same pathways. In addition, however, cytokine pleiotropy and redundancy can be at least partially explained, respectively, by the ability of certain cytokines to signal via more than one type of receptor complex and by the sharing of an individual receptor component by more than one cytokine. We will herein summarize a range of different systems wherein cytokine receptor components are shared, discussing the implications thereof. For type I cytokines, these include the sharing of the common β chain, βc, by interleukin-3 (IL-3),1 IL-5, and granulocyte-macrophage colony-stimulating factor (GM-CSF); the sharing of gp130 by IL-6, IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), novel neurotrophin-1/B cell-stimulating factor-3/cardiotrophin-like cytokine (NNT-1/BSF-3/CLC), and cardiotrophin-1 (CT-1); the sharing of LIFRβ by LIF, OSM, CNTF, NNT-1/BSF-3/CLC, and CT-1; the sharing of CNTFRα by CNTF and NNT-1/BSF-3/CLC; the sharing of IL-12Rβ1 by IL-12 and IL-23; the sharing of γc by IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21; the sharing of IL-2Rβ by IL-2 and IL-15; the sharing of IL-4Rα and IL-13Rα1 by IL-4 and IL-13; and the sharing of IL-7Rα by IL-7 and thymic stromal lymphopoietin (TSLP) (Table I). The cytokines that can signal via more than one complex include IL-2, IL-4, human OSM, and murine IL-3. For type II cytokines, we discuss the sharing of IL-10Rβ by IL-10 and IL-22, the sharing of IL20Rα and IL-20Rβ by IL-19, IL-20, and IL-24, and the sharing of IL-22Rα by IL-20, IL-22, and IL-24.Table ISharing of receptor subunits by multiple type I cytokinesShared subunitOther componentsLigandIL-3RαβcHuman or murine IL-3βIL-3Murine IL-3βcIL-3RαIL-3GM-CSFRαGM-CSFIL-5RαIL-5gp130IL-6RαIL-6IL-11RαIL-11CNTFRα and LIFRβCTNFLIFRβLIFLIFRβOSM (human)OSMRβOSM (human or murine)LIFRβ and CNTFRαNNT-1/BSF-3/CLCLIFRβ and ?CT-1LIFRβgp130LIFgp130OSM (human)CNTFRα, gp130CNTFgp130 and CNTFRαNNT-1/BSF-3/CLCgp130 and ?CT-1CNTFRαgp130 and LIFRβCNTFgp130 and LIFRβNNT-1/BSF-3/ CLC plus CLF1IL-12Rβ1IL-12Rβ2IL-12IL-23RIL-23γcIL-2Rα, IL-2RβIL-2 (high affinity receptor)IL-2RβIL-2 (intermediate affinity receptor)IL-4RαIL-4IL-7RαIL-7IL-9RαIL-9IL-15Rα, IL-2RβIL-15IL-21RαIL-21IL-2RβγcIL-2 (high affinity receptor)IL-2Rα, γcIL-2 (intermediate affinity receptor)IL-15Rα, γcIL-15IL-4RαγcIL-4 (type I receptor)IL-13Rα1IL-4 (type II receptor)IL-13Rα1IL-4RαIL-4 (type II receptor)IL-4RαIL-13IL-7RαγcIL-7TSLPRTSLP Open table in a new tab The basic understanding of type I cytokine-receptor interactions comes from the original studies on growth hormone, a type I cytokine (4de Vos A.M. Ultsch M. Kossiakoff A.A. Science. 1992; 255: 306-312Crossref PubMed Scopus (2023) Google Scholar) (reviewed in Ref. 1Leonard W.J. Paul W.E. Fundamental Immunology. 4th Ed. Lippincott-Raven Publishers, Philadelphia1999: 741-774Google Scholar). Growth hormone was shown to bind to a growth hormone receptor homodimer; remarkably, two different parts of the ligand interacted with relatively similar regions of the receptor (4de Vos A.M. Ultsch M. Kossiakoff A.A. Science. 1992; 255: 306-312Crossref PubMed Scopus (2023) Google Scholar). The basic model is that growth hormone binds first to one monomer via a high affinity “Site 1” and then the second receptor monomer interacts with this complex, contacting growth hormone via “Site 2.” In the case of the growth hormone system, the complex is further stabilized via a receptor-receptor interaction site denoted as “Site 3” (4de Vos A.M. Ultsch M. Kossiakoff A.A. Science. 1992; 255: 306-312Crossref PubMed Scopus (2023) Google Scholar). Although this represents a homodimeric receptor system, it is easy to envision how receptor heterodimers would form if the second growth hormone receptor monomer were a distinctive receptor component. Such a second component is represented for example by the common cytokine receptor β chain (βc), gp130, and the common cytokine receptor γ chain (γc), which are discussed below. IL-3, IL-5, and GM-CSF are hematopoietic cytokines with IL-3 having actions as a “multi-CSF” on multiple lineages, IL-5 being essential for eosinophil expansion, and GM-CSF acting mainly on granulocytes and macrophages/monocytes. Each of these cytokines has a distinctive α chain (IL-3Rα, IL-5Rα, and GM-CSFRα), but they all share a common β chain, βc, in both humans and mice (5Hayashida K. Kitamura T. Gorman D.M. Arai K. Yokota T. Miyajima A. Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 9655-9659Crossref PubMed Scopus (519) Google Scholar, 6Kitamura T. Sato N. Arai K. Miyajima A. Cell. 1991; 66: 1165-1174Abstract Full Text PDF PubMed Scopus (509) Google Scholar, 7Tavernier J. Devos R. Cornelis S. Tuypens T. Van der Heyden J. Fiers W. Plaetinck G. Cell. 1991; 66: 1175-1184Abstract Full Text PDF PubMed Scopus (497) Google Scholar) (reviewed in Ref. 8Miyajima A. Mui A.L. Ogorochi T. Sakamaki K. Blood. 1993; 82: 1960-1974Crossref PubMed Google Scholar). Interestingly, in mice but not in humans there is an IL-3-specific β chain as well, denoted βIL-3 (8Miyajima A. Mui A.L. Ogorochi T. Sakamaki K. Blood. 1993; 82: 1960-1974Crossref PubMed Google Scholar, 9Itoh N. Yonehara S. Schreurs J. Gorman D.M. Maruyama K. Ishii A. Yahara I. Arai K. Miyajima A. Science. 1990; 247: 324-327Crossref PubMed Scopus (290) Google Scholar). Despite the presumed importance of IL-3, IL-5, and GM-CSF for hematopoiesis, disruption of βc in a murine knock-out model does not cause a severe defect within the hematopoietic system, although signaling in response to IL-5 and GM-CSF is disrupted, and these mice exhibit alveolar proteinosis and defective eosinophil responses (10Nishinakamura R. Nakayama N. Hirabayashi Y. Inoue T. Aud D. McNeil T. Azuma S. Yoshida S. Toyoda Y. Arai K. et al.Immunity. 1995; 2: 211-222Abstract Full Text PDF PubMed Scopus (272) Google Scholar, 11Robb L. Drinkwater C.C. Metcalf D., Li, R. Kontgen F. Nicola N.A. Begley C.G. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 9565-9569Crossref PubMed Scopus (248) Google Scholar). As expected, signaling in response to IL-3 remains normal because of the presence of βIL-3, with IL-3 signaling being eliminated only in the context of βc/IL-3 double knock-out mice (12Nishinakamura R. Miyajima A. Mee P.J. Tybulewicz V.L. Murray R. Blood. 1996; 88: 2458-2464Crossref PubMed Google Scholar). IL-6, IL-11, LIF, OSM, CNTF, NNT-1/BSF-3/CLC, and CT-1 are seven cytokines, some of which were discovered in very different assay systems. Collectively, these cytokines exert multiple actions ranging from the immune system to the cardiovascular system to the central nervous system, but all of them share the gp130 signal-transducing molecule as a component of their receptors (13Taga T. Kishimoto T. Annu. Rev. Immunol. 1997; 15: 797-819Crossref PubMed Scopus (1298) Google Scholar, 14Miyajima A. Kinoshita T. Tanaka M. Kamiya A. Mukouyama Y. Hara T. Cytokine Growth Factor Rev. 2000; 11: 177-183Crossref PubMed Scopus (130) Google Scholar, 15Bravo J. Heath J.K. EMBO J. 2000; 19: 2399-2411Crossref PubMed Google Scholar, 16Senaldi G. Varnum B.C. Sarmiento U. Starnes C. Lile J. Scully S. Guo J. Elliott G. McNinch J. Shaklee C.L. Freeman D. Manu F. Simonet W.S. Boone T. Chang M.-S. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 11458-11463Crossref PubMed Scopus (198) Google Scholar). IL-6 was originally identified as a B cell differentiation factor, but it also can exert effects related to T cell growth, and on many other cell types as well, including the induction of acute phase proteins. IL-11 is a stromal factor that can induce acute phase proteins and has a number of hematopoietic related effects as well, cooperating with IL-3 and stem cell factor. LIF can suppress the differentiation of pluripotent stem cells, inhibit monocyte differentiation of M1 cells, and inhibit adipogenesis, as well as exert effects in the central nervous system. LIF is identical to cholinergic neural differentiation factor. OSM was originally identified based on its ability to inhibit growth of a melanoma cell line, but it is also a growth potentiator, for example for Kaposi's sarcoma. CNTF is primarily known for its ability to promote neuronal survival. NNT-1/BSF-3/CLC also supports survival of chicken embryo motor and sympathetic neurons, whereas in mice it potentiates effects of IL-1 and IL-6 and has B cell stimulating capability. NNT-1/BSF-3/CLC associates with the soluble receptor cytokine-like factor-1 (CLF-1) as a second ligand for CNTFRα (17Elson G.C.A. Lelievre E. Guillet C. Chevalier S. Plun-Favreau H. Froger J. Suard I. de Cognac A.B. Delneste Y. Bonnefoy H. 2000; PubMed Scopus Google Scholar). although CT-1 was discovered based on its actions on cells, it has a wide range of including actions with the hematopoietic and neural systems as a number of these factors have overlapping actions, but they are also As these cytokines all share the gp130 signal-transducing molecule (13Taga T. Kishimoto T. Annu. Rev. Immunol. 1997; 15: 797-819Crossref PubMed Scopus (1298) Google Scholar, 14Miyajima A. Kinoshita T. Tanaka M. Kamiya A. Mukouyama Y. Hara T. Cytokine Growth Factor Rev. 2000; 11: 177-183Crossref PubMed Scopus (130) Google Scholar, 15Bravo J. Heath J.K. EMBO J. 2000; 19: 2399-2411Crossref PubMed Google Scholar, 16Senaldi G. Varnum B.C. Sarmiento U. Starnes C. Lile J. Scully S. Guo J. Elliott G. McNinch J. Shaklee C.L. Freeman D. Manu F. Simonet W.S. Boone T. Chang M.-S. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 11458-11463Crossref PubMed Scopus (198) Google Scholar). gp130 was originally as a with of the IL-6 receptor (13Taga T. Kishimoto T. Annu. Rev. Immunol. 1997; 15: 797-819Crossref PubMed Scopus (1298) Google Scholar). The IL-11 receptor and the LIF receptor LIFRβ and oncostatin M can via receptors and gp130 or LIFRβ and the CNTF receptor and the NNT-1/BSF-3/CLC receptor and and the CT-1 receptor LIFRβ and IL-6 and IL-11 not whereas LIF, OSM, CNTF, NNT-1/BSF-3/CLC, and CT-1 As human OSM can signal two types of one of which LIFRβ and one of which does As of an of IL-6 the gp130 was in in to certain in hematopoiesis, of gp130 in a because of a defect in K. T. M. S. A. Tanaka T. H. M. T. T. Hirabayashi T. Y. Tanaka K. C. K. Yoshida N. Kishimoto T. Proc. Natl. Acad. Sci. U. S. A. 1996; PubMed Scopus Google Scholar). does not to a defect in IL-6 signaling but to other cytokines such as LIFRβ disruption in a neural defect M. M. A. 1995; PubMed Scopus Google Scholar, D. B.C. T. et 1995; PubMed Google Scholar). IL-12 is an cytokine that of an that associates with a that a soluble cytokine The a receptor that of IL-12Rβ1 and and is for cell differentiation J. L. U. Annu. Rev. Immunol. PubMed Scopus Google Scholar, G. Immunol. PubMed Google Scholar). IL-12 denoted was identified R. Y. N. J. K. F. E. T. M. Gorman D. J. S. D. de R. C. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar). The which via IL-12Rβ1 and C. M. J. E. M. J. S. R. W. J. T. S. C. Gorman D. D.M. de R. J. Immunol. PubMed Scopus Google Scholar) but not R. Y. N. J. K. F. E. T. M. Gorman D. J. S. D. de R. C. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar). The common cytokine receptor γ chain was originally as a component of the IL-2 receptor and denoted as the chain, to of the first that were discovered T. H. K. Ishii N. S. Tanaka N. H. M. K. Science. 1992; PubMed Scopus Google Scholar). et H. S. W.S. W.J. Cell. 1993; Full Text PDF PubMed Scopus Google Scholar) then discovered that in in denoted as a by of T and but with normal B defect in a component of the IL-2 receptor in this was that humans and mice of the IL-2 normal T cell and cell H. T. T. A. I. 1991; PubMed Scopus Google Scholar, R. T. S. C. R. H. N. Proc. Natl. Acad. Sci. U. S. A. 1989; PubMed Scopus Google Scholar, K. R. N. J. 1990; PubMed Scopus (130) Google Scholar). it was that exert actions the IL-2 system H. S. W.S. W.J. Cell. 1993; Full Text PDF PubMed Scopus Google and it was that was a component of other cytokine receptors as well, in the of its to In to IL-2, the receptors for IL-4, IL-7, IL-9, IL-15, and also γc (reviewed in Ref. W.J. Rev. Immunol. PubMed Scopus Google Scholar) and this of cytokines is sometimes denoted as the IL-2 of cytokines. The of U. McNeil T. Murray R. J. 1995; PubMed Scopus Google Scholar) and P.J. E. B.C. J. 1994; PubMed Scopus Google Scholar) mice as well as that of humans with in the human have that the of T in from defective IL-7 signaling A. W.J. PubMed Scopus Google Scholar). range of in as well as the of mice of or that defective cell from defective signaling M. S. de C. F. A. Blood. 1996; 88: PubMed Google Scholar, M. M. N. K. L. K. P.J. K. S. J. 2000; PubMed Scopus Google Scholar, Boone S. T. S. A. Full Text Full Text PDF PubMed Scopus Google Scholar). of the cytokines have the ability to at least in vitro, as T cell growth factors W.J. Rev. Immunol. PubMed Scopus Google Scholar). IL-2 is the T cell growth factor that T cell but it also including for example in cell and in the of natural killer (1Leonard W.J. Paul W.E. Fundamental Immunology. 4th Ed. Lippincott-Raven Publishers, Philadelphia1999: 741-774Google Scholar). IL-4 is essential for T cell differentiation and for G. M. H. G. 1993; PubMed Scopus Google Scholar). IL-7 is essential for T cell in both humans and mice and for B cell in mice but not is for cell growth and N.A. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar). is essential for cell and T cell M. M. N. K. L. K. P.J. K. S. J. 2000; PubMed Scopus Google Scholar, Boone S. T. S. A. Full Text Full Text PDF PubMed Scopus Google Scholar, S. I. J. Full Text Full Text PDF PubMed Scopus Google Scholar). The of a more identified is not in The is similar to IL-2Rβ K. K. D. W.J. Proc. Natl. Acad. Sci. U. S. A. 2000; PubMed Scopus Google Scholar, J. A. A. C. J. W. J. S. S. M. C. J. D. J. F. S. K. S. C. M. C. 2000; PubMed Scopus Google Scholar). In vitro, has a on T cell can B cell and can inhibit B cell by plus IL-4 J. A. A. C. J. W. J. S. S. M. C. J. D. J. F. S. K. S. C. M. C. 2000; PubMed Scopus Google Scholar). was also to the of from human in in response to ligand plus J. A. A. C. J. W. J. S. S. M. C. J. D. J. F. S. K. S. C. M. C. 2000; PubMed Scopus Google but a more that it the actions of M. A.L. M. Full Text Full Text PDF PubMed Scopus Google Scholar). to be primarily in such as and K. K. D. W.J. Proc. Natl. Acad. Sci. U. S. A. 2000; PubMed Scopus Google Scholar, J. A. A. C. J. W. J. S. S. M. C. J. D. J. F. S. K. S. C. M. C. 2000; PubMed Scopus Google Scholar). are by T cell receptor in human K. K. D. W.J. Proc. Natl. Acad. Sci. U. S. A. 2000; PubMed Scopus Google Scholar). There are types of receptors for the affinity receptor affinity receptor IL-2Rβ and and high affinity receptor and (reviewed in 1Leonard W.J. Paul W.E. Fundamental Immunology. 4th Ed. Lippincott-Raven Publishers, Philadelphia1999: 741-774Google and W.J. Rev. Immunol. PubMed Scopus Google Scholar). The and high affinity receptors are the The IL-4 receptor on T IL-4Rα plus but there is a second IL-4 receptor II IL-4 The IL-7 receptor IL-7Rα plus The receptor plus The receptor and both the IL-2 and receptors both IL-2Rβ and γc and only in distinctive α the receptor plus γc (reviewed in Ref. W.J. Rev. Immunol. PubMed Scopus Google Scholar). IL-4 is related to T As the type I IL-4 receptor IL-4Rα plus IL-4Rα was originally as a receptor for IL-4 T. D. A. D. J. et 1989; Full Text PDF PubMed Scopus Google Scholar). Overlapping actions of IL-4 and and a range of other including the of the same and the ability of IL-4 and to for that IL-4 and would share a receptor component G. EMBO J. 1993; PubMed Scopus Google Scholar, G. J. de R. G. de J. 1993; PubMed Scopus Google Scholar, N. J. S. Blood. 1994; PubMed Google Scholar, M. M. L. A. J. S. et al.Immunity. 1995; 2: Full Text PDF PubMed Scopus Google Scholar, C. A. J. 1995; Full Text Full Text PDF PubMed Scopus (130) Google Scholar) (reviewed in Ref. L. Immunol. 1996; Full Text PDF PubMed Scopus Google Scholar). Interestingly, the type II IL-4 on and certain other cell of IL-4Rα plus and this complex also is the receptor Metcalf D. W.S. Nicola N.A. Proc. Natl. Acad. Sci. U. S. A. 1996; PubMed Scopus Google N. W.S. W.J. J. 1996; Full Text Full Text PDF PubMed Scopus Google Scholar) Interestingly, whereas IL-4 primarily binds primarily binds There is a second which binds with affinity than IL-13Rα1 but which to be a inhibitory receptor D. M. S. N. J. 1996; Full Text Full Text PDF PubMed Scopus Google Scholar, H. M. J. Immunol. Google Scholar). IL-4 and to be for differentiation mice also a differentiation defect C.L. S. G. Murray R. R. Full Text Full Text PDF PubMed Scopus Google Scholar). As expected, disruption of the in mice in defective differentiation N. F. H. Paul W.E. Proc. Natl. Acad. Sci. U. S. A. 1997; PubMed Scopus Google Scholar). In to its to is essential for and for A. Full Text Full Text PDF PubMed Scopus Google Scholar, M. C.L. Science. PubMed Scopus Google Scholar, G. M. R. F. D.M. D. M. Science. PubMed Scopus Google Scholar). TSLP was identified as a factor that was in the of a thymic stromal cell line, and was of the growth of a cell line, S. A. D. A. 1994; Google Scholar). Interestingly, the receptor for TSLP its distinctive receptor chain, as well as IL-7Rα A. K. H. A. W.J. Immunol. 2000; PubMed Scopus Google Scholar, U. K. W. N.A. P.J. R. J. 2000; PubMed Scopus Google Scholar). TSLP and IL-7 share IL-7Rα as a common receptor component to explain the of mice is more severe than that in because the signaling in response to both IL-7 and TSLP and the only signaling in response to Interestingly, which can for γc in the context of and which γc as one from IL-7 to TSLP are both similar to is particularly of which is the in with to γc A. K. H. A. W.J. Immunol. 2000; PubMed Scopus Google Scholar). was by A. K. H. A. W.J. Immunol. 2000; PubMed Scopus Google Scholar, U. K. W. N.A. P.J. R. J. 2000; PubMed Scopus Google Scholar, K. T. T. T. T. N.A. K. T. Kitamura T. Blood. 2000; PubMed Google Scholar, T. A. Y. Y. A. H. 2000; PubMed Scopus Google Scholar). the as one that an receptor K. T. T. T. T. N.A. K. T. Kitamura T. Blood. 2000; PubMed Google Scholar, T. A. Y. Y. A. H. 2000; PubMed Scopus Google Scholar). group identified it as an that to the receptor but then it was that this receptor was in the A. K. H. A. W.J. Immunol. 2000; PubMed Scopus Google Scholar). group the of TSLP as well as its receptor U. K. W. N.A. P.J. R. J. 2000; PubMed Scopus Google Scholar, P.J. K. D. A. N.A. K. J. 2000; PubMed Scopus Google Scholar). TSLP only binds to but affinity to the of and of TSLP to its receptor in different cell the for and were and A. K. H. A. W.J. Immunol. 2000; PubMed Scopus Google P.J. K. D. A. N.A. K. J. 2000; PubMed Scopus Google the for the is but to different of of the different receptor components in cell TSLP supports and B in vitro, as S. A. D. A. 1994; Google Scholar) and also in also to have a for growth of P.J. K. D. A. N.A. K. J. 2000; PubMed Scopus Google Scholar). TSLP and were and human TSLP was to the of and to induce in Gorman D.M. T. M. J. H. de R. J. Immunol. PubMed Scopus Google Scholar, H. D. M. A. 15: PubMed Scopus Google Scholar, Y. K. T. T. M. Kitamura T. PubMed Scopus (53) Google Scholar). with the and IL-19, IL-20, denoted for T denoted as for melanoma and are as type II cytokines (reviewed in Vos A.M. Ultsch M. Kossiakoff A.A. Science. 1992; 255: 306-312Crossref PubMed Scopus (2023) Google de R. A. Annu. Rev. Immunol. 19: PubMed Scopus Google Scholar, L. C. D. J. Immunol. PubMed Scopus Google Scholar, M. R. J. Full Text Full Text PDF PubMed Scopus Google Scholar, H. S. H. A. S. H. Immunol. Full Text Full Text PDF PubMed Scopus Google Scholar). IL-10 was the first of these molecules discovered as a that inhibit the of cytokines de R. A. Annu. Rev. Immunol. 19: PubMed Scopus Google Scholar). The receptor for IL-10 of plus The of cytokines exert a range of actions, partially as is based on the sharing of receptor de R. A. Annu. Rev. Immunol. 19: PubMed Scopus Google Scholar, L. C. D. J. Immunol. PubMed Scopus Google Scholar, M. R. J. Full Text Full Text PDF PubMed Scopus Google Scholar, H. S. H. A. S. H. Immunol. Full Text Full Text PDF PubMed Scopus Google Scholar) as in of receptor subunits by multiple type II cytokinesShared subunitOther Open table in a new tab I and type II cytokines exhibit both cytokine pleiotropy and There are multiple wherein these cytokines share receptor can be as cytokine receptor wherein a chain such as βc, gp130, or IL-22Rα as of more than a In addition, there are of can be as possible cytokine receptor wherein more than one receptor form can for a cytokine. include the and high affinity of the IL-2 type I and type II IL-4 murine IL-3 receptors that βc or βIL-3, and two of OSM, IL-20, and these represent receptor for or represent two of receptors that exert distinctive actions is for IL-2 wherein the affinity form is on whereas the high affinity form is essential for the of T further how similar many type I cytokines are to other and the of multiple type I cytokine receptor it is possible that of the cytokines and their receptor is a that has the of new distinctive cytokine functions. The same is also to interferons and the IL-10 of type II cytokines. As on the of cytokine-receptor a understanding of these systems will the specific for the ability of cytokines to with more than one receptor and the ability of a receptor chain to with multiple cytokines.
Source: Journal of Biological Chemistry
Authors: Katsutoshi Ozaki, Warren J. Leonard
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,430
OpenAlex ID: W1996606664
